Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Redcare Pharmacy N.V. (SHPPF)
USD64.80
+0.00 (+0.00%)
NL OTC Healthcare Medical - Pharmaceuticals
Address
Erik de Rodeweg 11–13 5975 WD
Sevenum, NL
Sevenum, NL
CEO
Olaf Heinrich
Website
redcare-pharmacy.com
IPO
2021-01-06
ISIN NL0012044747
Also trades on
Deutsche Börse · RDC.DE (EUR)
Deutsche Börse · SAE.DE (EUR)
Other OTC · SAEYY (USD)
Other OTC · SHPPF (USD)
Description
Redcare Pharmacy N.V. operates an extensive network of online pharmacies, serving customers in a number of European nations including Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a broad array of health and wellness products, from prescribed and over-the-counter medicines to a variety of beauty and personal care items typically found in pharmacies, as well as dietary supplements. Founded in 2001, the enterprise was formerly recognized as Shop Apotheke Europe N.V. before officially adopting the name Redcare Pharmacy N.V. in June 2023. Its headquarters are situated in Sevenum, the Netherlands.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD64.80
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1
Beta
1.46
Float Shares
14.63M
Free Float %
71.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -36.82% | -41.85% | -39.76% | -69.52% | -5.18% | -79.56% | -75.62% | -75.62% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
64.80
Quality scores
Altman Z-Score
3.09
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+24.0% ★ Q1'26: +18.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+17.3% Q1'26: +3.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-1.9% Q1'26: +1.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-0.8% Q1'26: -0.4% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%-3.4% Q1'26: -2.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×9.11× Q1'26: 6.67× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 1 EPS Ana. |
Dec 2027 8 Rev. Ana. 1 EPS Ana. |
Dec 2028 6 Rev. Ana. 1 EPS Ana. |
Dec 2029 7 Rev. Ana. 1 EPS Ana. |
Dec 2030 7 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
177.39M
est: 186.61M (-4.9%)
|
283.99M
est: 343.04M (-17.2%)
|
539.71M
est: 622.81M (-13.3%)
|
701.01M
est: 787.42M (-11.0%)
|
968.06M
est: 1.18B (-18.3%)
|
1.06B
est: 1.21B (-12.0%)
|
1.20B
est: 1.30B (-7.0%)
|
1.80B
est: 1.97B (-8.8%)
|
2.37B
est: 2.38B (-0.2%)
|
2.94B
est: 2.95B (-0.3%)
|
3.43B
3.39B – 3.47B
+16.3% YoY
|
3.84B
3.76B – 3.89B
+12.0% YoY
|
4.18B
4.11B – 4.23B
+8.7% YoY
|
4.72B
4.64B – 4.79B
+13.1% YoY
|
5.28B
5.19B – 5.35B
+11.7% YoY
|
| EBITDA |
-10.78M
est: -689.5K (-1,462.7%)
|
-15.56M
est: -1.27M (-1,127.9%)
|
-17.98M
est: -2.30M (-681.1%)
|
-26.83M
est: -2.91M (-822.2%)
|
10.89M
est: -4.38M (+348.9%)
|
-42.35M
est: -4.45M (-851.2%)
|
-36.11M
est: -4.79M (-654.4%)
|
50.94M
est: -7.29M (+798.6%)
|
28.16M
est: -6.76M (+516.6%)
|
45.58M
est: -8.39M (+643.4%)
|
-9.75M
-9.88M – -9.64M
-16.3% YoY
|
-10.93M
-11.08M – -10.68M
-12.0% YoY
|
-11.88M
-12.04M – -11.68M
-8.7% YoY
|
-13.43M
-13.61M – -13.20M
-13.1% YoY
|
-15.00M
-15.21M – -14.75M
-11.7% YoY
|
| EBIT |
-11.62M
est: -5.74M (-102.3%)
|
-19.16M
est: -10.56M (-81.4%)
|
-31.15M
est: -19.17M (-62.5%)
|
-34.70M
est: -24.24M (-43.1%)
|
-5.17M
est: -36.47M (+85.8%)
|
-69.32M
est: -37.10M (-86.8%)
|
-75.62M
est: -39.87M (-89.6%)
|
-6.35M
est: -60.75M (+89.5%)
|
-40.06M
est: -74.47M (+46.2%)
|
-23.79M
est: -92.42M (+74.3%)
|
-107.47M
-108.88M – -106.25M
-16.3% YoY
|
-120.39M
-122.03M – -117.70M
-12.0% YoY
|
-130.88M
-132.63M – -128.64M
-8.7% YoY
|
-147.97M
-149.95M – -145.44M
-13.1% YoY
|
-165.31M
-167.52M – -162.48M
-11.7% YoY
|
| Net Income |
-18.45M
est: -32.66M (+43.5%)
|
-21.36M
est: -40.25M (+46.9%)
|
-33.61M
est: -41.76M (+19.5%)
|
-36.27M
est: -53.27M (+31.9%)
|
-16.77M
est: -14.10M (-18.9%)
|
-74.19M
est: -58.18M (-27.5%)
|
-77.65M
est: -76.94M (-0.9%)
|
-12.04M
est: -12.53M (+3.9%)
|
-45.46M
est: -36.50M (-24.6%)
|
-37.69M
est: -17.39M (-116.7%)
|
-16.38M
-16.66M – -16.01M
+5.8% YoY
|
14.08M
13.76M – 14.32M
+185.9% YoY
|
45.00M
44.00M – 45.78M
+219.7% YoY
|
140.20M
137.08M – 142.64M
+211.6% YoY
|
209.86M
205.19M – 213.51M
+49.7% YoY
|
| SGA |
33.30M
est: 31.26M (+6.5%)
|
55.64M
est: 57.47M (-3.2%)
|
78.50M
est: 104.34M (-24.8%)
|
108.71M
est: 131.91M (-17.6%)
|
145.24M
est: 198.43M (-26.8%)
|
196.88M
est: 201.88M (-2.5%)
|
244.24M
est: 216.98M (+12.6%)
|
267.44M
est: 330.57M (-19.1%)
|
356.65M
est: 395.86M (-9.9%)
|
427.10M
est: 491.29M (-13.1%)
|
571.27M
564.80M – 578.77M
+16.3% YoY
|
639.97M
625.68M – 648.69M
+12.0% YoY
|
695.73M
683.82M – 705.04M
+8.7% YoY
|
786.60M
773.14M – 797.13M
+13.1% YoY
|
878.77M
863.73M – 890.53M
+11.7% YoY
|
| EPS |
-2.03
est: -1.62 (-25.1%)
|
-2.25
est: -2.00 (-12.5%)
|
-2.79
est: -2.08 (-34.4%)
|
-2.78
est: -2.65 (-5.0%)
|
-1.17
est: -0.70 (-66.9%)
|
-4.15
est: -2.89 (-43.5%)
|
-4.32
est: -3.82 (-13.0%)
|
-0.63
est: -0.62 (-1.2%)
|
-2.26
est: -1.82 (-24.5%)
|
-1.87
est: -0.86 (-116.3%)
|
-0.81
-0.83 – -0.80
+5.8% YoY
|
0.70
0.68 – 0.71
+185.9% YoY
|
2.24
2.19 – 2.28
+219.7% YoY
|
6.97
6.82 – 7.09
+211.6% YoY
|
10.44
10.20 – 10.62
+49.7% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-59.32M
OE per share TTM
-2.95
Owner's Yield
-6.53%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-13.0K
Shares Outstanding
20.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Olaf Heinrich | CEO & Member of Managing Board | 608.8K | male |
| Theresa Holler | Chief Operating Officer & Member of the Managing Board | 556.5K | female |
| Lode Fastré | Chief Information Officer & Member of Management Board | 441.0K | male |
| Hendrik Krampe | Chief Financial Officer & Member of Management Board | 424.2K | male |
| Dirk Bruse | Chief Commercial Officer & Member of Management Board | 422.9K | male |
| Stephan Weber | Co-Founder & Member of Supervisory Board | 374.2K | male |
| Marc Fischer | Co-Founder & Advisor | 362.8K | male |
| Monica Ambrosi | Associate Director of Investor Relations | — | female |
| Michael Köhler | Co-Founder & Chairperson of Supervisory Board | — | male |
| Patrick Schneider | Chief Sales Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHPPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
